

VOLUME CONTENTS AND INDEX

No. 1, MARCH 1993

Vascular Derived Growth Factors: Cell Biology, Pathophysiology, and Pharmacology.
Alex Bobik and Julie H. Campbell

I. Introduction	2
II. Development of vascular endothelial and smooth muscle cells	2
A. Embryonic origins of endothelial and smooth muscle cells	2
B. Structural and growth characteristics of endothelial cells	3
C. Structural and growth characteristics of smooth muscle cells	3
D. Pericytes	4
E. Pseudoendothelium	4
III. Pathophysiological aspects of blood vessel growth, lesions, and remodeling	5
A. Vascular lesions in atherosclerosis	5
B. Intimal thickening	5
C. Vascular hypertrophy in hypertension	7
D. Angiogenesis	8
IV. Endothelium- and smooth muscle-derived growth factors	9
A. Platelet-derived growth factor	9
B. Fibroblast growth factors	13
C. Transforming growth factors- β	16
D. Miscellaneous	20
1. Cytokines	20
2. Endothelins	21
3. Insulin-like growth factors	22
4. Platelet-, monocyte/macrophage-, and T-lymphocyte-derived growth factors	23
V. Heparan sulphate: a vascular cell growth regulator	24
VI. Pharmacological manipulation of growth factor activity	26
A. Atherosclerosis	26
1. Calcium channel blockers	26
2. Hydroxymethylglutaryl-coenzyme A reductase inhibitors	27
3. Miscellaneous	27
B. Vascular restenosis	27
1. Angiotensin-converting enzyme inhibitors	28
2. Recombinant chimeric toxins	28
3. Miscellaneous	29
C. Hypertension	29
1. Antihypertensive agents	29
D. Angiogenesis	30
1. Angiostatic steroids	30
2. Interferons	31
3. Protamine	31
4. Tissue-derived inhibitors	31
E. Conclusions	31
VII. References	32

Caffeine as an Analgesic Adjuvant: A Review of Pharmacology and Mechanisms of Action. Jana Sawynok and Tony L. Yaksh

I. Introduction	45
II. Caffeine metabolism and kinetics	45
A. Absorption	45
B. Metabolism	46
C. Clearance	46
D. Blood-brain transfer	46
E. Factors governing caffeine disposition	47
1. Age	47
2. Genetics	47
3. Exercise	47
4. Pregnancy	47
5. Disease	47
6. Smoking/enzyme inducers	47
7. Drugs	47
F. Effect of caffeine on drug kinetics and metabolism	47

1. Caffeine effects on gastric absorption	47
2. Caffeine effects on organ perfusion	48
3. Effects on disposition of analgesic drugs	48
G. Summary	48
III. Pharmacology of caffeine	49
A. Overview of caffeine and methylxanthine actions	49
B. Adenosine receptor antagonism	49
C. Phosphodiesterase inhibition	50
D. 5'-Nucleotidase inhibition	50
E. Calcium movements	50
F. Other pharmacological interactions of caffeine	51
1. Benzodiazepine/ γ -aminobutyric acid A receptors	51
2. Interaction with noradrenaline	51
3. Arachidonic acid metabolites	51
G. Summary	51
IV. Analgesic and adjuvant actions of caffeine in humans	52
A. Clinical studies with caffeine	52
1. Effects of caffeine alone on pain behavior in humans	52
2. Analgesic adjuvant actions of caffeine in humans	52
B. Factors influencing efficacy of caffeine as an analgesic adjuvant	52
1. Caffeine dose	52
2. Test stimulus and pain state	56
3. Stimulus intensity	56
C. Summary	57
V. Analgesic and adjuvant action of caffeine in nonhumans	57
A. Nociceptive response paradigms	57
B. Effects of caffeine on nociceptive thresholds	58
C. Caffeine interactions with nonopioid analgesic drugs	58
D. Caffeine interactions with opioid analgesics	59
E. Summary	59
VI. Psychomotor effects of caffeine	60
A. Psychomotor effects in humans	60
1. Effects on electroencephalogram	60
2. Vigilance	60
3. Well-being	60
4. Reinforcing properties	61
5. Anxiogenic properties	61
B. Psychomotor effects in nonhumans	61
1. Stimulant properties	61
2. Anxiogenic properties of caffeine	62
C. Summary	62
VII. Peripheral mechanisms of caffeine interactions with nociceptive processing	62
A. Chemical mediators in peripheral nociceptive transduction	62
1. Histamine	63
2. Lipidic acids	63
3. Kinins	63
4. Primary afferent peptides	63
5. Purines	63
B. Peripheral adenosine receptors and nociception	63
1. Evocation of a pain and hyperalgesic state by adenosine	63
2. Mechanisms of algogenic actions of adenosine	64
C. Calcium flux, phosphodiesterase, and 5'-nucleotidase inhibition	66
D. Interactions with inflammatory intermediaries	67
E. Summary	67
VIII. Central mechanisms of caffeine interactions with nociceptive processing	67
A. Neuraxial effects of caffeine on nociceptive transmission	67
1. Central adenosine receptors and pain transmission	68
2. Central noradrenergic systems	68
3. Benzodiazepine/ γ -aminobutyric acid interactions	69
4. Calcium fluxes and phosphodiesterase inhibition	70
B. Methylxanthine dependence and withdrawal	70
C. Alterations in the affective component of pain	71
D. Summary	71
IX. Interactions between caffeine and analgesic systems	72
A. Caffeine-nonsteroidal anti-inflammatory drug interactions	72
1. Pharmacokinetics	72
2. Peripheral action	72
3. Central action	72
4. Headache	73

B. Caffeine-opioid interactions	74
1. Pharmacokinetics	74
2. Peripheral action	74
3. Central action	74
X. Concluding comments	75
XI. References	75
Neutral Endopeptidase 24.11: Structure, Inhibition, and Experimental and Clinical Pharmacology. Bernard P. Roques, Florence Noble, Valérie Daugé, Marie-Claude Fournié-Zaluski, and Ann Beaumont	
I. Introduction	88
II. Neutral endopeptidase 24.11 a pharmacologically relevant multisubstrate-metabolizing enzyme	89
III. Neutral endopeptidase 24.11 purification and assay of neutral endopeptidase 24.11 activity	90
IV. Substrate specificity and mechanism of action of neutral endopeptidase 24.11	91
V. Design of selective neutral endopeptidase 24.11 and aminopeptidase N inhibitors	93
A. Development of selective inhibitors of neutral endopeptidase 24.11	93
1. Thiol inhibitors	93
2. Carboxyl inhibitors	95
3. Bidentate inhibitors	95
4. Phosphorus-containing inhibitors	96
B. Aminopeptidase N and dipeptidyl peptidase inhibitors	96
VI. Development of mixed inhibitors of neutral endopeptidase 24.11 and aminopeptidase N and of neutral endopeptidase and angiotensin-converting enzyme	96
VII. Molecular biology of neutral endopeptidase 24.11	97
A. Complementary DNA cloning and sequencing	97
B. Site-directed mutagenesis	98
C. Human neutral endopeptidase (common acute lymphoblastic leukemia antigen) gene ..	99
VIII. Localization of neutral endopeptidase 24.11	100
A. Central nervous system	100
1. Distribution and ontogenesis of neutral endopeptidase 24.11 in spinal cord and meninges of humans and rats	100
2. Lesion studies and cellular localization of neutral endopeptidase 24.11 in brain tissues	101
3. Cellular and subcellular distribution of neutral endopeptidase 24.11 in the central nervous system	103
4. In situ hybridization of neutral endopeptidase 24.11 messenger RNA in the central nervous system	105
B. Localization of neutral endopeptidase 24.11 in peripheral tissues	105
C. Pre- and postnatal ontogeny of neutral endopeptidase 24.11 in central and peripheral tissues	106
D. Neutral endopeptidase 24.11 in physiological fluids	107
IX. Modulation of neutral endopeptidase 24.11 expression and possible role as regulator of protein turnover at the cell surface	107
X. Pharmacological studies	109
A. In vitro and in vivo studies of neuropeptide degradation by neutral endopeptidase 24.11 and aminopeptidase N	109
B. Limited antinociceptive effects of selective neutral endopeptidase 24.11 or aminopeptidase N inhibitors	112
C. Enhanced analgesic responses induced by mixed inhibitors of enkephalin-degrading enzymes	114
D. Inhibitor-induced spinal antinociception	115
E. Analgesic effects of selective and mixed inhibitors in chronic pain	117
F. Interactions between the cholecystokinin and enkephalin systems in the control of pain	118
G. Tolerance, dependence, and side effects of selective and mixed inhibitors of neutral endopeptidase 24.11 and aminopeptidase N	118
H. Effect of peptidase inhibitors on morphine withdrawal	121
I. Behavioral effects of neutral endopeptidase 24.11 and neutral endopeptidase 24.11/aminopeptidase N inhibitors	121
J. Gastrointestinal effects of enkephalin-degrading enzyme inhibitors and their clinical use as antidiarrheal agents	125
K. Role of neutral endopeptidase 24.11 in airways	126

L. Inhibition of neutral endopeptidase 24.11-induced inactivation of atrial natriuretic peptide: pharmacological and clinical implications	127
M. Possible roles of the common acute lymphoblastic leukemia antigen identified as neutral endopeptidase 24.11 on lymphoblastic cells	131
XI. Conclusions and perspectives	132
XII. References	133

NO. 2, JUNE 1993

Cardiac α_1 -Adrenoceptors: An Overview. André-Terzic, Michel Pucat, Guy Vassort, and Stephen M. Vogel

I. Introduction	147
II. Characterization of myocardial α_1 -adrenoceptors	148
A. Demonstration, species differences, and developmental changes of cardiac α_1 -adrenoceptors	148
B. Cardiac α_1 -adrenoceptor subtypes	148
III. Cardiac α_1 -adrenoceptor signal transduction pathways	149
A. Coupling of cardiac α_1 -adrenoceptors to G-regulatory proteins	149
B. Second messengers	149
IV. Cellular effects resulting from the stimulation of cardiac α_1 -adrenoceptors	152
A. Effects on the cardiac action potential and ionic currents	152
B. Effects on intracellular H ⁺ , Na ⁺ , and Ca ²⁺ and on ionic transport mechanisms	154
C. Metabolic effects	155
V. Physiological and pathophysiological consequences of α_1 -adrenoceptor stimulation	156
A. α_1 -Adrenoceptors and inotropy	156
1. Characteristics of the α_1 -adrenergic positive inotropic effect	157
2. α_1 -Adrenoceptor-mediated positive inotropic effect in pathological conditions	158
3. Proposed mechanisms of the α_1 -adrenergic positive inotropic effect	159
a. Evidence for and against a causal relationship between α_1 -adrenergic effects on the action potential and positive inotropic effect	159
b. Is there a causal relationship between α_1 -adrenoceptor-mediated stimulation of the breakdown of phosphatidyl inositol and contractile force?	160
c. Evidence that α_1 -adrenoceptor stimulation increases the myofibrillar responsiveness to Ca ²⁺ . Could the diacylglycerol limb play a role in mediating the effects of α_1 -adrenoceptor agonists on contractile force and myofibrillar sensitization?	161
B. Chronotropic effects	163
C. Arrhythmogenic and other detrimental effects	164
D. Induction of gene expression and stimulation of hypertrophy	165
VI. Existence of functional α_1 -adrenoceptors in human cardiac tissue	166
A. In vitro studies	166
B. In vivo studies	167
VII. Concluding remarks	167
VIII. References	168

Recent Research on the Biological Activity of Suramin. Theo E. Voogd, Eugene L. M. Vansterkenburg, J. Wilting, and Lambert H. M. Janssen

I. Introduction	177
II. Chemistry	178
A. Structure-activity relationships	178
B. Analytical methods	178
III. Absorption and distribution	179
A. Dosage	179
B. Pharmacokinetics	180
IV. Pharmacological actions of suramin	180
A. Action on trypanosomes	180
B. Action on filaria	182
C. Action on human immunodeficiency virus	183
D. Action on other viruses	184
E. Interaction with receptors	185
F. Disturbance of growth factor-receptor interaction	187
G. Action on cancers	189
V. Pathological actions of suramin	190
A. Toxicity	190
B. Action on blood	191
C. Suramin-induced mucopolysaccharidoses	191
D. Immunological actions	192
E. Teratogenic aspects	193
F. Adrenal pathology	194

G. Vortex keratopathy	194
H. Suramin-induced polyneuropathy	195
I. Skin reactions	195
VI. Chemotherapy with suramin	196
A. Treatment of trypanosomiasis	196
B. Treatment of onchocerciasis	196
C. Treatment of acquired immunodeficiency syndrome	197
D. Treatment of hepatitis B virus infection	197
E. Treatment of metastasizing adrenal carcinoma and other metastatic carcinomas	197
VII. Concluding remarks	199
VIII. References	199
Angiotensin II Receptors and Angiotensin II Receptor Antagonist. Pieter B. M. W. M. Timmermans, Pancras C. Wong, Andrew T. Chiu, William F. Herblin, Pamela Benfield, David J. Carini, Robert J. Lee, Ruth R. Wexler, Jo Anne M. Seye, and Ronald D. Smith	
I. Introduction	206
II. Nonpeptide angiotensin II receptor antagonists	207
A. Discovery of nonpeptide receptor antagonists	207
B. Evolving class of nonpeptide angiotensin II receptor antagonists	209
III. Defining angiotensin II receptor heterogeneity	213
A. Nomenclature	213
B. Tissue distribution of receptor subtypes	213
C. Angiotensin II receptor subtype 2	214
D. Atypical angiotensin II receptors and binding sites	216
IV. Receptor cloning and new angiotensin II receptor subtype 1	216
V. In vitro profile of an angiotensin II receptor subtype 1-selective antagonist	219
A. Affinity and binding characteristics for angiotensin II receptor subtype 1 receptor	219
B. Selectivity and specificity	220
C. Inhibition of angiotensin II second-messenger systems	220
D. Inhibition of angiotensin II tissue and organ responses	221
VI. In vivo profile of an angiotensin II receptor subtype 1-selective antagonist	222
A. Selective inhibition of angiotensin II pressor responses in pithed rats	222
B. Selective inhibition of angiotensin II pressor responses in experimental animals	223
VII. Characterizing the lack of agonist effect of nonpeptide antagonists (cellular, tissue, and whole animal responses)	223
VIII. Inhibiting the angiotensin system in vivo	224
A. Acute hemodynamic effects	224
B. Effects on renal function	224
1. Renal vasoconstrictor effect of angiotensin II	225
2. Renal glomerular and tubular effects of angiotensin II	225
3. Renal effect in animal models of human diseases	225
4. Mechanistic studies of renal effects of angiotensin-converting enzyme and nitric oxide inhibitors	225
5. Renal effect of angiotensin II receptor subtype 2-selective antagonist	226
C. Antihypertensive effects	226
1. Renal hypertensive rats	226
2. Deoxycorticosterone acetate-salt hypertensive rats	227
3. Spontaneously hypertensive rats	227
4. Transgenic hypertensive rats	228
5. Other hypertensive models	228
D. Effects on neurotransmitter release	228
E. Blocking cardiac hypertrophy and failure	229
F. Renal protective effects	231
G. Inhibiting the response to vascular injury	232
H. Antimitogenic activity	232
I. Effects on nonvascular smooth muscle	233
J. Effects on reproductive organs	234
K. Central effects	234
1. Vasopressin release	234
2. Drinking/thirst	235
3. Behavior	236
L. Interactions with other peptide systems	237
1. Nitric oxide/endothelium-derived relaxing factor	237
2. Atrial natriuretic factor	239
IX. Bioavailability and pharmacokinetic considerations	240
X. Demonstrating angiotensin II antagonism and antihypertensive efficacy in humans	240
XI. Future perspectives	241
XII. References	242

NO. 3, SEPTEMBER 1993

Pharmacology of Lower Urinary Tract Smooth Muscles and Penile Erectile Tissues. Karl-Erik-Anderson

I. Introduction	254
II. Detrusor	255
A. Anatomy	255
B. Mechanical properties	255
C. Electrophysiology	255
D. Excitation-contraction coupling	256
E. Mechanisms of activation	257
1. Myogenic activity	257
2. Cholinergic mechanisms	257
3. Adrenergic mechanisms	260
4. Nonadrenergic, noncholinergic mechanisms	262
F. Inhibition of activation mechanisms	273
1. Membrane hyperpolarization—potassium channel openers	273
2. Inhibition of calcium influx—calcium antagonists	274
G. Effects of sexual hormones	275
1. Estrogen and progesterone	275
2. Testosterone	276
3. Pregnancy	276
III. Trigone	276
IV. Bladder neck and urethra	276
A. Anatomy	276
B. Electrophysiology	277
C. Mechanisms of activation	277
1. Myogenic activity	277
2. Adrenergic mechanisms	277
3. Cholinergic mechanisms	278
4. Nonadrenergic, noncholinergic mechanisms	279
D. Effects of sexual hormones	281
1. Estrogen and progesterone	281
E. Penile erectile tissues	281
A. Anatomy	282
B. Mechanism of erection	282
C. Electrophysiology	283
D. Mechanisms of activation	283
1. Myogenic activity	283
2. Adrenergic mechanisms	283
3. Cholinergic mechanisms	284
4. Nonadrenergic, noncholinergic mechanisms	285
E. Inhibition of activation mechanisms	291
1. Membrane hyperpolarization—potassium channel openers	291
2. Inhibition of calcium influx—calcium antagonists	292
F. Effects of sexual hormones	292
VI. Conclusion	292
VII. References	293

Neuropharmacology of Quinolinic and Kynurenic Acids. T. W. Stone

I. Introduction	310
II. Kynureanine biosynthesis	311
A. Kynureninase and kynureanine hydroxylase	312
1. Inhibition of kynureninase	313
B. L-Kynureanine aminotransferase	313
C. 3-Hydroxyanthranilic acid oxygenase	314
D. Quinolinic acid phosphoribosyltransferase	315
III. Kynureamines in brain	315
A. Quinolinic acid	316
1. Formation and removal of quinolinate	318
2. Transport of quinolinic acid	319
3. Blood-brain barrier	320
B. L-Kynureanine and kynurenic acid	320
1. 3-Hydroxypykynurene	323
2. Blood-brain barrier	323
3. Synthesis of kynureate from indolepyruvate	324
IV. Pharmacology	324
A. Quinolinic acid	325

1. Are quinolinate receptors a subtype of N-methyl-D-aspartate receptor?	325
2. Intracellular studies	327
3. Patch-clamp studies	327
4. Myenteric plexus	328
B. Neurochemical effects of kynureptides	328
1. Effects on uptake and release of amino acids	328
2. Effects on other neuroactive agents	329
3. Luteinising hormone	329
C. Kynurenic acid	330
1. Selectivity of kynurenamide	330
2. Kynurenic acid and kainate receptors	331
3. Kynurenic acid and metabotropic sites	331
4. Kynurenic acid and synaptic transmission	331
5. Site of action of kynurenic acid	336
6. Glycine site	337
7. Activity of kynurenamide analogues	341
V. Behaviour	345
A. Motor activity	345
B. Sex and behavioural recovery	345
C. Learning and memory	345
D. Sleep	346
E. Anxiety	346
F. Nociception and opioid interactions	346
G. Miscellaneous behaviours	347
VI. Pathological states	347
A. Neurotoxicity	348
B. Mechanism of neurotoxicity	348
1. Presynaptic receptors	349
2. Transcription factors	349
3. Apoptosis	349
4. Cytoskeletal disruption	349
5. Lipid peroxidation	350
6. Other kynureptides	350
C. Neuroprotection against quinolinate	350
1. Quinolinate as an experimental tool	351
D. Huntington's disease	352
1. Kynureptide concentrations in Huntington's disease	355
E. Seizures	357
1. Kynureptide concentrations in seizures	357
2. Kynureptides and seizure induction	357
3. Electrophysiological epileptiform activity	360
4. Ischaemia	361
5. Concussion	361
6. Hypoglycaemia	362
7. Hepatic damage	362
8. Infection	363
9. Acquired immunodeficiency syndrome	363
10. Other neurodegenerative diseases	364
11. Miscellaneous diseases	365
12. Ageing	365
13. Alzheimer's disease	365
VII. Growth and development	366
VIII. Summary	366
IX. References	367

No. 4, DECEMBER 1993

Hepatic and Extrahepatic Pathobiology of Bacterial Lipopolysaccharides. James A. Hewett and Robert A. Roth

I. General introduction	382
A. Structure of bacterial lipopolysaccharide	382
B. Exposure to lipopolysaccharide	383
1. Gram-negative bacterial infection	383
2. Absorption from the gastrointestinal tract	383
C. Clearance and detoxification of lipopolysaccharide	384
D. Pathogenic role of lipopolysaccharide in Gram-negative bacterial infection	384
1. Mortality during systemic sepsis	384
2. Tissue injury from local infection	385

II. Interactions between lipopolysaccharide and mammalian cells in vitro	385
A. Lipopolysaccharide receptors	385
1. Binding of lipopolysaccharide to cell surface receptors	385
2. Binding of lipopolysaccharide to soluble lipopolysaccharide-binding proteins	386
3. Nonspecific interactions with membranes	387
B. Cytotoxicity	387
C. Stimulation of mediator release from mammalian cells	388
D. Intracellular signal transduction pathways	389
III. Extrahepatic effects of lipopolysaccharide in vivo	389
A. Circulatory shock	390
B. Disseminated intravascular coagulation	391
C. Kidneys	391
D. Gastrointestinal tract	392
E. Lungs	393
IV. Hepatic effects of lipopolysaccharide in vivo	393
A. Normal liver function and structure	394
B. Liver and lipopolysaccharide	394
1. Clinical manifestations of liver injury	394
2. Animal models	395
3. Morphological and functional alterations	395
C. Direct effects of lipopolysaccharide on the liver	396
1. Cholestasis	396
2. Hepatic lipid metabolism	396
D. Indirect (host-mediated) effects of lipopolysaccharide on the liver	397
1. Neutrophils	397
2. Kupffer cells	398
3. Cytokines	400
4. Coagulation system	401
5. Arachidonic acid metabolites	401
E. Interactions among mediators in the pathogenesis of lipopolysaccharide-induced liver injury	402
F. Summary of mediator relationships in lipopolysaccharide-induced liver injury: a hypothesis	403
V. Conclusion	403
VI. References	404

Cytochrome P450 and Monoclonal Antibodies. Harry V. Gelboin

I. Introduction	413
A. Monoclonal antibodies: production and properties	414
B. Homogeneous monoclonal antibodies from impure antigens (cytochrome P450s): hybridoma cloning as cytochrome P450 purification system	415
C. Monoclonal antibodies for cytochrome P450 Research	415
D. Monoclonal antibodies and epitope specificity	416
E. Complementary monoclonal antibody-directed "reaction phenotyping" and cytochrome P450 cDNA expression	416
F. Monoclonal antibody-directed immunoassay of cytochrome P450	417
G. Cloning and regulation of cytochrome P450s and cytochrome P450 peptide processing	417
H. Implications for ecogenetics, pharmacogenetics, and risk assessment	417
II. Library of monoclonal antibodies	418
A. Antigen preparation for monoclonal antibody production	427
III. Detection of cytochrome P450s with monoclonal antibodies	428
A. Competitive radioimmunoassay to determine epitope relatedness	429
IV. Monoclonal antibody-directed immunohistochemistry	431
V. Immunopurification	433
VI. Reaction phenotyping of the metabolic contribution of individual cytochrome P450s	435
VII. Monoclonal antibodies for analyses of human tissues	445
A. cDNA-expressed human and rodent cytochrome P450s for analysis of monoclonal antibody specificity	445
B. Monoclonal antibody analyses of cytochrome P450s in human tissue	445
VIII. Epilogue	450
IX. References	451

Atrial Natriuretic Factor Receptors and Signal Transduction Mechanisms. Madhu B. Anand-Srivastava and George J. Trachte

I. Introduction	457
II. Atrial natriuretic factor receptors	457
A. Overview	457

B. Radioligand-binding studies	457
1. Vasculature	457
2. Kidney	458
3. Adrenal gland	459
4. Heart	460
5. Lung	460
6. Endocrine organs	460
7. Neurons	460
8. Platelets	461
C. Atrial natriuretic factor R ₁ receptors	461
D. Atrial natriuretic factor R ₂ receptors/cANF receptors	462
E. Summary	464
III. Signal transduction mechanisms	464
A. Overview	464
B. Guanylyl cyclase/cyclic guanosine monophosphate signal transduction system	465
C. Adenylyl cyclase/cyclic adenosine monophosphate signal transduction system	466
1. Vasculature	466
2. Kidney	466
3. Adrenal	467
4. Heart	467
5. Lung	467
6. Endocrine tissues	467
7. Neuronal tissue	468
8. Platelets	468
9. Other tissues	468
10. Characterization of atrial natriuretic factor R ₂ receptor-mediated inhibition of adenylyl cyclase guanosine triphosphate dependency	468
D. Phospholipase C-mediated signal transduction system	469
E. Altered ion conductances	469
F. Production of eicosanoids	469
G. Production of endothelium-derived relaxing factor	470
IV. Biological actions of atrial natriuretic factor	470
A. Vascular effects of atrial natriuretic factor	470
1. Role of guanylyl cyclase activation in atrial natriuretic factor vasodilation	470
2. Inhibitory effects of atrial natriuretic factor on vascular adenylyl cyclase	471
3. Atrial natriuretic factor effects on phospholipase C in the vasculature	471
4. Atrial natriuretic factor effects on ionic currents in vascular smooth muscle	471
5. Atrial natriuretic factor effects on eicosanoid and endothelium-derived relaxing factor production in the vasculature	472
6. Conclusion concerning vascular atrial natriuretic factor transduction mechanisms	472
B. Atrial natriuretic factor effects on the kidney	472
1. Role of renal guanylyl cyclase	472
2. Inhibition of renal adenylyl cyclase	473
3. Effects on renal phospholipase C activity	474
4. Effects on renal ion currents	474
5. Role of renal eicosanoids and endothelium-derived relaxing factor	474
6. Conclusion regarding atrial natriuretic factor renal transduction mechanisms	475
C. Effects of atrial natriuretic factor on aldosterone production	475
1. Guanylyl cyclase involvement in adrenal effects of atrial natriuretic factor	475
2. Role of adenylyl cyclase inhibition in atrial natriuretic factor effects on aldosterone secretion	476
3. Atrial natriuretic factor effects on phospholipase C in adrenal glomerulosa	476
4. Atrial natriuretic factor effects on ion fluxes in the adrenal glomerulosa	476
5. Atrial natriuretic factor effects on adrenal eicosanoids or endothelium-derived relaxing factor	477
6. Conclusion on atrial natriuretic factor adrenal signal transduction pathways	477
D. Cardiac effects of atrial natriuretic factor	477
1. Role of guanylyl cyclase in mediating atrial natriuretic factor cardiac responses	477
2. Role of adenylyl cyclase inhibition in cardiac responses to atrial natriuretic factor	478
3. Atrial natriuretic factor effects on phospholipase C activity in the heart	478
4. Atrial natriuretic factor effects on ion fluxes in the heart	478
5. Atrial natriuretic factor effects on cardiac endothelium-derived relaxing factor or eicosanoid synthesis	478
6. Conclusions regarding atrial natriuretic factor cardiac transduction mechanisms	478
E. Pulmonary effects of atrial natriuretic factor	478
1. Role of guanylyl cyclase in pulmonary effects of atrial natriuretic factor	479
2. Role of adenylyl cyclase inhibition in mediating atrial natriuretic factor effects in the lung	479

3. Conclusions regarding pulmonary transduction pathways	479
F. Endocrine effects of atrial natriuretic factor	479
1. Atrial natriuretic factor effects on guanylyl cyclase in endocrine organs	480
2. Atrial natriuretic factor effects on adenylyl cyclase activity in endocrine tissues	480
3. Atrial natriuretic factor effects on ion conductance in endocrine tissue	481
4. Conclusion regarding atrial natriuretic factor signal transduction mechanisms in endocrine systems	481
G. Atrial natriuretic factor neuromodulatory effects	481
1. Role of guanylyl cyclase activation in neuronal responses to atrial natriuretic factor	482
2. Role of adenylyl cyclase inhibition in atrial natriuretic factor neuromodulatory effects	482
3. Atrial natriuretic factor effects on neuronal ionic currents	482
4. Role of eicosanoid production in atrial natriuretic factor neuromodulatory effects	483
5. Conclusions regarding atrial natriuretic factor signaling pathways within neurons	483
H. Atrial natriuretic factor effects on platelets	483
1. Role of guanylyl cyclase in atrial natriuretic factor responses in platelets	483
2. Role of adenylyl cyclase inhibition on platelet actions of atrial natriuretic factor	483
3. Conclusions regarding atrial natriuretic factor actions in platelets	483
V. Atrial natriuretic factor receptor antagonists	484
VI. Pathological alterations in transduction mechanisms	485
A. Introduction	485
B. Hypertension	485
1. Cardiovascular tissues	485
2. Kidney	486
3. Adrenal	486
4. Neural	486
5. Platelets	486
6. Summary	487
C. Congestive heart failure	487
D. Potential mechanisms accounting for altered atrial natriuretic factor receptor regulation	487
VII. General conclusions	488
VIII. References	489